<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653415</url>
  </required_header>
  <id_info>
    <org_study_id>1072.6120.11.2020</org_study_id>
    <nct_id>NCT04653415</nct_id>
  </id_info>
  <brief_title>Large Doses of Methylprednisolone Combined With Gabapentin in Total Knee Arthroplasty</brief_title>
  <official_title>The Impact of Pre-emptive Large Doses of Methylprednisolone Combined With Gabapentin on Pain Treatment and Convalescence After Total Knee Arthroplasty in Elderly: A Double-blind Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to assess whether administration of gabapentin and&#xD;
      methylprednisolone as &quot;pre-emptive analgesia&quot; in a group of patients above 65 years of age&#xD;
      would be effective in complex pain management therapy following total knee arthroplasty&#xD;
      (TKA). For the study investigators will qualify one hundred seventy, above 65 years old&#xD;
      patients. The participants will be double-blind randomized into two groups: the study and&#xD;
      controls The study group will receive as &quot;pre-emptive&quot; analgesia a single dose of 300 mg oral&#xD;
      gabapentin and 125 mg intravenous methylprednisolone, while the others placebo.&#xD;
      Perioperatively, all the patients will receive opioid and nonopioid analgesic agents&#xD;
      calculated for 1 kg of body weight. Investigators will measure the levels of inflammatory&#xD;
      markers (leukocytosis, C-reactive protein - CRP), pain intensity level at rest (numerical&#xD;
      rating scale - NRS), the life parameters and all complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study was to assess whether administration of gabapentin and&#xD;
      methylprednisolone as &quot;pre-emptive analgesia&quot; in a group of patients above 65 years of age&#xD;
      would be effective in complex pain management therapy following total knee arthroplasty&#xD;
      (TKA).170 patients operated on due to unilateral TKA will be double-blinded randomized into&#xD;
      two groups: the study and the controls. Exclusion criteria are: clinical situation that 1/&#xD;
      restricted glucocorticoid administration: diabetes type 1 and 2, CRP levels above normal&#xD;
      values (≥5 mg/l), chronic steroid treatment, peptic ulcers treated in the past 30 days and&#xD;
      2/and the chronic pain in the course of gonarthrosis, high intensity requiring use opioids.&#xD;
&#xD;
      The participants of the study will be subjected to the standardized procedure of subarachnoid&#xD;
      anesthesia with subsequent unilateral femoral nerve block at the operated side, followed by&#xD;
      the surgical procedure - unilateral TKA. The study group will receive as &quot;pre-emptive&quot;&#xD;
      analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone,&#xD;
      while the others placebo. Prior to anesthesia induction, the patients receive: anti-infection&#xD;
      prophylactics intravenous cephazolin 2.0 g, for hemostasis control - tranexamic acid 1.0 g,&#xD;
      an anti-emetic agent - ondansetron 8 mg. Fluid supply (crystalloids) will be standardized: 12&#xD;
      ml/kg in the first hour of surgery and 6 ml/kg in the following hours, packed red blood cells&#xD;
      if blood loss exceeded 600 ml and hemoglobin concentration &lt;10g/l during the time of&#xD;
      operation. Pain management will be carried out based on the results of the NRS scales at&#xD;
      rest. Every 6 hours NRS will be checked and intravenous PCA (patient-controlled analgesia)&#xD;
      oxycodone hydrochloride, if pain was ≥4 points NRS or intravenous paracetamol, metamizole, if&#xD;
      the pain was 2 - 4 NRS points will be administered, all pain medications will be calculated&#xD;
      for 1 kg of body weight. In keeping with the ERAS (Enhanced Recovery After Surgery) protocol,&#xD;
      on the day of surgery the patients will receive orally fluids and meals, will be mobilized&#xD;
      and rehabilitated.&#xD;
&#xD;
      The study was approved by the institutional review board (nr 1072.6120.11.2020). Oral and&#xD;
      written informed consent to participate in the study will be collected from all participants&#xD;
      of the study. The statistical analysis of the groups will be performed to asess the&#xD;
      demographic dates, life parameters, general condition in keeping with the ASA (American&#xD;
      Society of Anesthesiology), POSSUM (Physiologic and Operative Severity Score for the&#xD;
      enUmeration of Mortality and Morbidity) score, total dose of analgesic medications&#xD;
      administered parenterally calculated for 1 kg of body mass in response to value of NRS at&#xD;
      rest on day 0, time of administration the first dose, and duration of peripheral nerve block.&#xD;
      On the day of surgery and on subsequent days, determinations will be made of glycemia levels&#xD;
      and inflammatory markers: C-reactive protein (CRP) and leukocytosis levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two groups: the study and controls</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants of the study are blinded to receive methylprednisolone with gabapentin (the study group) or placebo (the controls group). Only nurse knows if administer drug or placebo. Both outcome assessor and investigator are blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity assessed by NRS</measure>
    <time_frame>change in every 6 hours on day 0</time_frame>
    <description>The level of postoperative pain measured in the numerical rating scale (NRS) at rest (minimum 0 - no pain, maximum 10 - the maximum of pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the dose of parenteral analgesics agents</measure>
    <time_frame>24 hours</time_frame>
    <description>Dose of oxycodone hydrochloride in mg/kg body weight, paracetamol in mg/kg body weight, metamizole in g/kg body weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein (CRP) level</measure>
    <time_frame>change in 0,1,2,3 days after surgery</time_frame>
    <description>C-reactive protein (CRP) level measured in mg/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leukocytosis level</measure>
    <time_frame>change in 0,1,2,3 days after surgery</time_frame>
    <description>Leukocytosis level measured in µL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>0 day after surgery</time_frame>
    <description>The occurrence of adverse effects that would delay early rehabilitation, possible complication development, perioperative mortality to the POSSUM scale, comorbidities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>The occurrence of adverse effects that would delay early rehabilitation, possible complication development, perioperative mortality to the POSSUM scale, comorbidities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>2 day after surgery</time_frame>
    <description>The occurrence of adverse effects that would delay early rehabilitation, possible complication development, perioperative mortality to the POSSUM scale, comorbidities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>3 day after surgery</time_frame>
    <description>The occurrence of adverse effects that would delay early rehabilitation, possible complication development, perioperative mortality to the POSSUM scale, comorbidities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>14 day after surgery</time_frame>
    <description>The occurrence of adverse effects that would delay early rehabilitation, possible complication development, perioperative mortality to the POSSUM scale, comorbidities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of femoral nerve blockade</measure>
    <time_frame>on the day of surgery</time_frame>
    <description>The time of femoral nerve block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose level</measure>
    <time_frame>change in 0,1,2,3 days after surgery</time_frame>
    <description>The level of glucose in blood in mmol/l</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean age</measure>
    <time_frame>the day of surgery</time_frame>
    <description>Mean age in years</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean hospitalization time</measure>
    <time_frame>from admission to hospital till 14 days after surgery</time_frame>
    <description>Mean hospitalization time in days</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean postoperative hospitalization time</measure>
    <time_frame>change from 0 till 14 days after surgery</time_frame>
    <description>Mean postoperative hospitalization time in days</description>
  </other_outcome>
  <other_outcome>
    <measure>Postoperative Mean Arterial Pressure (MAP)</measure>
    <time_frame>change in 0,1,2,3 days after surgery</time_frame>
    <description>Postoperative Mean Arterial Pressure (MAP) measured in mmHg</description>
  </other_outcome>
  <other_outcome>
    <measure>Postoperative pulse</measure>
    <time_frame>change in 0,1,2,3 days after surgery</time_frame>
    <description>Postoperative pulse (x/min)) measured in x/min</description>
  </other_outcome>
  <other_outcome>
    <measure>Postoperative saturation (Sp02) of the arterial blood</measure>
    <time_frame>change in 0,1,2,3 days after surgery</time_frame>
    <description>Postoperative saturation (Sp02) of the arterial blood measured in %</description>
  </other_outcome>
  <other_outcome>
    <measure>Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) morbidity</measure>
    <time_frame>the day of the surgery</time_frame>
    <description>Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) morbidity measured in %</description>
  </other_outcome>
  <other_outcome>
    <measure>Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) mortality</measure>
    <time_frame>the day of the surgery</time_frame>
    <description>Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) mortality measured in %</description>
  </other_outcome>
  <other_outcome>
    <measure>Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) physiological score</measure>
    <time_frame>the day of the surgery</time_frame>
    <description>Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) physiological score measured in points (minimum 12, maximum 96)</description>
  </other_outcome>
  <other_outcome>
    <measure>American Society of Anesthesiology Score (ASA)</measure>
    <time_frame>the day of the surgery</time_frame>
    <description>American Society of Anesthesiology Score (ASA), grade I-IV</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Arthroplasty Complications</condition>
  <condition>Knee Osteoarthritis</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Perioperative Complication</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study group will receive as &quot;pre-emptive&quot; analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - saline solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin 300mg</intervention_name>
    <description>The study group will receive as &quot;pre-emptive&quot; analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone 125 mg</intervention_name>
    <description>The study group will receive as &quot;pre-emptive&quot; analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone.</description>
    <arm_group_label>Study Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tablet</intervention_name>
    <description>The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution</description>
    <arm_group_label>Controls group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline 10 mL Injection</intervention_name>
    <description>The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution</description>
    <arm_group_label>Controls group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients over 65 years old operated on unilateral total knee arthroplasty&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diabetes type 1 and 2,&#xD;
&#xD;
          -  CRP levels above normal values (≥5 mg/l),&#xD;
&#xD;
          -  chronic steroid treatment,&#xD;
&#xD;
          -  peptic ulcers treated in the past 30 days,&#xD;
&#xD;
          -  chronic pain in the course of gonarthrosis,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital in Krakow</name>
      <address>
        <city>Krakow</city>
        <state>Malopolska</state>
        <zip>30688</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Gerbershagen HJ, Aduckathil S, van Wijck AJ, Peelen LM, Kalkman CJ, Meissner W. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures. Anesthesiology. 2013 Apr;118(4):934-44. doi: 10.1097/ALN.0b013e31828866b3.</citation>
    <PMID>23392233</PMID>
  </reference>
  <reference>
    <citation>Lamplot JD, Wagner ER, Manning DW. Multimodal pain management in total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty. 2014 Feb;29(2):329-34. doi: 10.1016/j.arth.2013.06.005. Epub 2013 Jul 11.</citation>
    <PMID>23850410</PMID>
  </reference>
  <reference>
    <citation>Kehlet H, Lindberg-Larsen V. High-dose glucocorticoid before hip and knee arthroplasty: To use or not to use-that's the question. Acta Orthop. 2018 Oct;89(5):477-479. doi: 10.1080/17453674.2018.1475177. Epub 2018 May 21.</citation>
    <PMID>29781366</PMID>
  </reference>
  <reference>
    <citation>Luna IE, Kehlet H, Petersen MA, Aasvang EK. Clinical, nociceptive and psychological profiling to predict acute pain after total knee arthroplasty. Acta Anaesthesiol Scand. 2017 Jul;61(6):676-687. doi: 10.1111/aas.12899. Epub 2017 May 16.</citation>
    <PMID>28508511</PMID>
  </reference>
  <reference>
    <citation>Jørgensen CC, Pitter FT, Kehlet H; Lundbeck Foundation Center for Fast-track Hip and Knee Replacement Collaborative Group. Safety aspects of preoperative high-dose glucocorticoid in primary total knee replacement. Br J Anaesth. 2017 Aug 1;119(2):267-275. doi: 10.1093/bja/aex190.</citation>
    <PMID>28854533</PMID>
  </reference>
  <reference>
    <citation>Hartman J, Khanna V, Habib A, Farrokhyar F, Memon M, Adili A. Perioperative systemic glucocorticoids in total hip and knee arthroplasty: A systematic review of outcomes. J Orthop. 2017 Apr 12;14(2):294-301. doi: 10.1016/j.jor.2017.03.012. eCollection 2017 Jun. Review.</citation>
    <PMID>28442852</PMID>
  </reference>
  <reference>
    <citation>Lindberg-Larsen V, Ostrowski SR, Lindberg-Larsen M, Rovsing ML, Johansson PI, Kehlet H. The effect of pre-operative methylprednisolone on early endothelial damage after total knee arthroplasty: a randomised, double-blind, placebo-controlled trial. Anaesthesia. 2017 Oct;72(10):1217-1224. doi: 10.1111/anae.13983. Epub 2017 Jul 26.</citation>
    <PMID>28744857</PMID>
  </reference>
  <reference>
    <citation>Gądek A, Liszka H, Zając M. The effect of pre-operative high doses of methylprednisolone on pain management and convalescence after total hip replacement in elderly: a double-blind randomized study. Int Orthop. 2021 Apr;45(4):857-863. doi: 10.1007/s00264-020-04802-8. Epub 2020 Sep 17.</citation>
    <PMID>32940751</PMID>
  </reference>
  <reference>
    <citation>Lee JK, Chung KS, Choi CH. The effect of a single dose of preemptive pregabalin administered with COX-2 inhibitor: a trial in total knee arthroplasty. J Arthroplasty. 2015 Jan;30(1):38-42. doi: 10.1016/j.arth.2014.04.004. Epub 2014 Apr 13.</citation>
    <PMID>24851793</PMID>
  </reference>
  <reference>
    <citation>Lubis AMT, Rawung RBV, Tantri AR. Preemptive Analgesia in Total Knee Arthroplasty: Comparing the Effects of Single Dose Combining Celecoxib with Pregabalin and Repetition Dose Combining Celecoxib with Pregabalin: Double-Blind Controlled Clinical Trial. Pain Res Treat. 2018 Aug 7;2018:3807217. doi: 10.1155/2018/3807217. eCollection 2018.</citation>
    <PMID>30174951</PMID>
  </reference>
  <reference>
    <citation>Osinski T, Bekka S, Regnaux JP, Fletcher D, Martinez V. Functional recovery after knee arthroplasty with regional analgesia: A systematic review and meta-analysis of randomised controlled trials. Eur J Anaesthesiol. 2019 Jun;36(6):418-426. doi: 10.1097/EJA.0000000000000983.</citation>
    <PMID>30950899</PMID>
  </reference>
  <reference>
    <citation>Berg U, BüLow E, Sundberg M, Rolfson O. No increase in readmissions or adverse events after implementation of fast-track program in total hip and knee replacement at 8 Swedish hospitals: An observational before-and-after study of 14,148 total joint replacements 2011-2015. Acta Orthop. 2018 Oct;89(5):522-527. doi: 10.1080/17453674.2018.1492507. Epub 2018 Jul 9.</citation>
    <PMID>29985681</PMID>
  </reference>
  <reference>
    <citation>Pamilo KJ, Torkki P, Peltola M, Pesola M, Remes V, Paloneva J. Fast-tracking for total knee replacement reduces use of institutional care without compromising quality. Acta Orthop. 2018 Apr;89(2):184-189. doi: 10.1080/17453674.2017.1399643. Epub 2017 Nov 21.</citation>
    <PMID>29160123</PMID>
  </reference>
  <reference>
    <citation>Shen S, Gao Z, Liu J. The efficacy and safety of methylprednisolone for pain control after total knee arthroplasty: A meta-analysis of randomized controlled trials. Int J Surg. 2018 Sep;57:91-100. doi: 10.1016/j.ijsu.2018.07.009. Epub 2018 Aug 16. Review.</citation>
    <PMID>30120990</PMID>
  </reference>
  <reference>
    <citation>Lei Y, Xie J, Xu B, Xie X, Huang Q, Pei F. The efficacy and safety of multiple-dose intravenous tranexamic acid on blood loss following total knee arthroplasty: a randomized controlled trial. Int Orthop. 2017 Oct;41(10):2053-2059. doi: 10.1007/s00264-017-3519-x. Epub 2017 May 31.</citation>
    <PMID>28567578</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 21, 2020</study_first_submitted>
  <study_first_submitted_qc>November 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>November 28, 2020</last_update_submitted>
  <last_update_submitted_qc>November 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jagiellonian University</investigator_affiliation>
    <investigator_full_name>Henryk Liszka</investigator_full_name>
    <investigator_title>Principial Investigator, Assisstant Professor</investigator_title>
  </responsible_party>
  <keyword>total knee arthroplasty</keyword>
  <keyword>pre-emptive analgesia</keyword>
  <keyword>methylprednisolone</keyword>
  <keyword>gabapentin</keyword>
  <keyword>opioid dose</keyword>
  <keyword>pain intensity</keyword>
  <keyword>infection rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

